2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
Primary Objective: Evaluation of the benefit of IABP counterpulsation in patients with diuretic-resistant congestive heart failure. Secondary Objective(s): - To lower the burden of disease/improve symptoms, to shorten duration of stay in the…